![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Chapter
Disease-Modifying Anti-rheumatic Drugs
Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, with a worldwide prevalence of about 1%. Targeting the synovial membrane, cartilage and bone, untreated RA leads to joint destructio...
-
Article
Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat
Febuxostat is a xanthine oxidoreductase inhibitor that has been developed to treat chronic gout. In healthy subjects, the pharmacokinetic parameters of febuxostat after multiple oral dose administration includ...
-
Reference Work Entry In depth
Disease-Modifying Antirheumatic Drugs: Overview
-
Reference Work Entry In depth
CD20 Inhibitors: Rituximab
-
Reference Work Entry In depth
Phosphodiesterase 4 Inhibitors: Apremilast and Roflumilast
-
Reference Work Entry In depth
Leflunomide
-
Reference Work Entry In depth
Interleukin-6 Inhibitor: Tocilizumab
-
Reference Work Entry In depth
Sulfasalazine and Related Drugs
-
Reference Work Entry In depth
Antimalarial Drugs
-
Reference Work Entry In depth
Gold Complexes
-
Living Reference Work Entry In depth
CD80/86 Inhibitors: Abatacept
-
Reference Work Entry In depth
Tetracyclines
-
Reference Work Entry In depth
Interleukin-1 (IL-1) Inhibitors: Anakinra, Rilonacept, and Canakinumab
-
Living Reference Work Entry In depth
Interleukin-1 (IL-1) Inhibitors: Anakinra, Rilonacept, and Canakinumab
-
Living Reference Work Entry In depth
Tumor Necrosis Factor (TNF) Inhibitors
-
Reference Work Entry In depth
Methotrexate
-
Reference Work Entry In depth
CD80/86 Inhibitors: Abatacept
-
Reference Work Entry In depth
Interleukin-12/23 Inhibitors: Ustekinumab
-
Reference Work Entry In depth
Tumor Necrosis Factor (TNF) Inhibitors
-
Living Reference Work Entry In depth
Disease-Modifying Anti-Rheumatic Drugs: Overview